The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Amifampridin (N07XX05)

Fluorouracil, combinations only (D11AF55)

Folic acid (B03BB01)

Formoterol & Fluticason (R03AK11)

Imiquimod (D06BB10)

Ivermectin (P02CF01)

Lamivudin & Tenofovirdisoproxil & Doravirin (J05AR24)

Lapatinib (L01EH01)

Maraviroc (J05AX09)

Mesalazine (A07EC02)

Pegvisomant (H01AX01)

Pimecrolimus (D11AH02)

Raltegravir (J05AJ01)

Sevelamer (V03AE02)

Vilanterol & Umeclidiniumbromid (R03AL03)

Xylometazolin (R01AA07)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest start date of the contract is 01.07.2023. Based on this, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest start date of the contract is 01.07.2023. Based on this, the contract period is a maximum of 24 months.